Market insights

Home » Market insights

Certara Launches Drug and Medical Device Market Access Newsletter

Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, announces the launch of Analytica Laser’s Market Access Radar, a three times weekly market access intelligence briefing. This market access data is also available via an easily searchable web portal at “As new health technologies face increasing scrutiny from payers [...]

Barriers Impede Biosimilar Market Entry into the US Despite the BPCIA

As a result of biosimilars slow entry into the US market, the FDA is taking proactive measures to ensure the continued growth of the biosimilars market by educating patients and physicians through online resources and information campaigns to encourage more competition and lowered prices of biologics, according to GlobalData, a leading data and analytics company. [...]

Tetra’s Fragile X Syndrome Drug Must Demonstrate Significant Therapeutic Benefits to Secure Market Share

BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the FDA in April 2018. However, by the time this drug launches, there could be a handful of new drugs already approved for FXS, according to GlobalData, a leading data and analytics [...]

Ensuring Medication Safety in the Elderly

Almost half of over-65s in England take at least five different drugs each day, according to a 2017 study conducted at the University of Cambridge. The increasing rates of polypharmacy, taking multiple medications simultaneously, means that prescribing for the elderly is becoming an increasingly important aspect of clinical patient care. Here, Oliver Pittock, Managing Director [...]

Chinese Pharma Regulatory Reforms Will Help to Attract Foreign Investment

China is the second largest pharmaceutical market in the world. Driven by a large population, increasing incidence of chronic diseases and growing investments in healthcare sector, the Chinese pharmaceutical market is forecast to grow at a compound annual growth rate of 30% from $123.7 billion in 2016 to $573.5bn in 2022. However, certain barriers such [...]

CPhI South East Asia Strengthens ASEAN Integration by Opening Thailand Edition in 2019

CPhI South East Asia – organised by UBM – has announced that from 2019 onwards it will alternate its annual location between the region’s two largest pharma economies, Indonesia and Thailand. In 2019, CPhI South East Asia will take place at the Queen Sirikit National Convention Center (QSNCC) in Bangkok, Thailand (12-14 March) before returning [...]

Age-Related Macular Degeneration Market Will Rocket to $11.5 Billion by 2026

Pharmaceutical sales within the age-related macular degeneration (AMD) markets were estimated to be $4.9 billion across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK and Japan) in 2016. This is expected to reach $11.5 billion in 2026, at an impressive compound annual growth rate (CAGR) of 8.9%, according to GlobalData, a leading [...]

bioLIVE to Introduce Global Biopharma Country Ranking

bioLIVE – the UBM bioprocessing and manufacturing event opening in October (9-11) in Madrid – announces that it is to build on the success of last year’s global small molecule country rankings by introducing a biologics manufacturing and processing league table. The results of which will rank the perception of the world’s largest biologics markets [...]

Although the US Dominates the Biosimilar Market, Brazil and South Korea are Gaining a Foothold

Biosimilars are becoming increasingly popular with pharmaceutical companies; however, knowing which markets have been saturated with biosimilars and which are open, remains an important consideration for pharma companies, observes GlobalData, a leading data and analytics company. Lisa Marris, Healthcare Analyst at GlobalData, commented: “The deal activity can provide a useful indication of which biosimilar drugs [...]

2018 is the Year for Making Strategic Alliances in DMD

There is currently no effective therapy to treat Duchenne muscular dystrophy (DMD), but recent years have witnessed an increase in deal activity that may lead to future treatments, according to GlobalData, a leading data and analytics company. Interest in DMD drugs has been increasing in the past 5 years, with a steady increase in the [...]